Study of the Effect of SR57667B on 18F-Dopa PET Imaging in Patients With Parkinson's Disease

Summary

* The primary objective is to study the effect of SR57667B at the dose of 4 mg/d on progression of dopaminergic nigro-striatal lesions assessed by 18F-Dopa PET imaging. * Secondary objectives are to assess the effect of SR57667B on symptomatic decline in patients with early PD, to assess the safety/tolerability of SR57667B in patients with early PD and to document plasma concentrations of SR57667 in patients with early PD.

Timeline

Start

2004-01

Primary completion

2007-03

Completion

2007-03

Drugs

Indications